Travere Therapeutics, Inc. TVTX
59.44
(1.18)
(1.95%)
as of 25 Sep
- Market cap
- $5.7B
- P/E
- 0.0×
Follow TVTX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (151.79%) | (32.57%) | (29.38%) | (410.76%) |
+8 more TTM periods Free account |
|
| (6.42%) | (3.88%) | (4.26%) | (16.98%) | ||
ROIC |
(18.31%) | (24.41%) | (37.84%) | (43.68%) | |
Return on Tangible Assets |
(9.32%) | (7.91%) | (9.07%) | (36.84%) | |
Average Days of Receivables |
49.77 | 59.43 | 59.60 | 69.50 | |
Free Cash Flow per Share |
0.16 | (0.31) | (0.23) | (1.21) | |
Free Cash Flow |
15.16 | (28.94) | (20.37) | (107.87) | |
Capital Expenditures |
(77.54) | (68.55) | (58.16) | (49.25) | |
Piotroski F-Score |
6.00 | 7.00 | 7.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
8.30% | 5.86% | 5.04% | (9.17%) | |
Accounts Receivable Turnover |
9.91 | 8.81 | 9.15 | 8.06 | |
Accounts Payable Turnover |
0.62 | 0.54 | 0.43 | 0.50 | |
Inventory Turnover |
1.39 | 1.48 | 1.71 | 1.74 | |
Average Days of Payables |
331.08 | 619.30 | 875.52 | 643.46 | |
Days of Inventory on Hand |
346.09 | 304.85 | 207.41 | 195.88 | |
Tax Rate |
0.01 | 0.02 | 0.02 | 0.00 | |
Research and Development Expense of Revenue |
38.41% | 40.32% | 41.98% | 48.08% | |
Selling, General and Administrative Expense of Revenue |
66.05% | 66.59% | 68.71% | 64.00% | |
Share Based Compensation of Revenue |
10.26% | 9.24% | 9.14% | 9.78% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(2.13) | (1.85) | (1.48) | 0.66 | |
Depreciation/Fixed assets |
18.75 | 19.40 | 14.41 | 12.01 | |
Capex/Depreciation |
(1.28) | (0.97) | (1.00) | (0.95) | |
Revenue per Share |
6.33 | 5.84 | 5.50 | 4.88 | |
Operating CF per Share |
0.99 | 0.43 | 0.42 | (0.66) | |
Capex per Share |
(0.83) | (0.75) | (0.65) | (0.55) | |
Capex to Sales |
0.13 | 0.13 | 0.12 | 0.11 | |
Net Profit Margin |
(7.35%) | (4.00%) | (5.21%) | (20.32%) |
Columns are period end dates